Pre-Congress Symposium 6
Oncology & Theranostics Committee / European Society for Radiotherapy and Oncology (ESTRO)
Wednesday, October 6, 14:00-17:00

Session Title
Oligocare Concept in Radiation Oncology

Chairperson
Daniela Oprea-Lager (Amsterdam, Netherlands)

Programme
14:00 - 14:30 Matthias Guckenberger (Zurich, Switzerland / ESTRO): Oligocare for Tailored Medicine
14:30 - 15:00 Marta Scorsetti (Pieve Emanuele, Italy): Radiation Oncologist’s Point of View
15:00 - 15:30 Egesta Lopci (Milan, Italy): Targeted Imaging and Therapy in Oligomets
15:30 - 15:45 Break
15:45 - 16:20 Piet Ost (Antwerp, Belgium): The Future of Imaging in Radiotherapy
16:20 - 16:55 Yolande Lievens (Ghent, Belgium): Ongoing Projects and Initiatives
16:55 - 17:00 Summary by Chairperson

Educational Objectives
1. To learn about the characterisation and classification of oligometastatic disease
2. To become familiar with the role of imaging in the detection of oligometastases
3. To get insight on the ongoing initiatives focusing of the treatments of oligometastatic disease

Summary
Oligometastatic disease represents a distinct cancer state localized between confined and systemically metastasised disease. Given this peculiar status, oligometastatic disease can potentially benefit from local consolidative and metastasis-directed therapies. Hence, international collaborations, comprising Oligocare initiative, are focusing on optimizing radical radiotherapy for oligometastatic cancer patients. Consequently, the correct definition and detection of oligometastases represents a crucial point for treatment management. Given the scarcity of biomarkers available for this purpose, modern imaging techniques have become the most relevant diagnostic methods for defining oligometastatic disease. Their impact on lesion detection, treatment planning and response assessment is constantly assessed and will represent a central point also for future trials. The current pre-symposium organized in collaboration with the European Society for Radiotherapy and Oncology aims to illustrate the current standard s and future perspectives in oligometastatic-directed therapies by illustrating the point of view of both radiation oncologists and nuclear medicine physicians.

Key Words
Oligometastatic disease; radiation therapy; targeted imaging; PET/CT; response assessment